Becton Dickinson & CO

Becton, Dickinson and Company announces the upcoming retirement of EVP Michael Garrison, with the BioPharma Systems segment to report directly to the CEO.

Becton, Dickinson and Company has resumed U.S. shipments of ChloraPrep following successful completion of additional final release testing.

Becton, Dickinson and Company's subsidiary issued 600 million in 3.855% notes due 2033 to refinance existing debt.

Becton, Dickinson and Company announces the permanent appointment of Vitor Roque as Executive Vice President and Chief Financial Officer, effective May 7, 2026, following his tenure as interim CFO.

Becton, Dickinson and Company announced robust second quarter fiscal 2026 financial results, exceeding expectations with revenue growth and adjusted diluted EPS, leading to an upward revision of full-year EPS guidance.

Becton, Dickinson and Company announced amendments to its bylaws on April 28, 2026, primarily updating advance notice provisions for contested elections.

Becton, Dickinson and Company (BD) reported its Q2 2026 financial results, detailing revenue growth and the impact of its recent spin-off of the Biosciences and Diagnostic Solutions business.

Becton, Dickinson and Company reported a 1.6% revenue increase and a 26.1% net income jump in Q1 2026, while completing its Biosciences and Diagnostic Solutions spin-off and planning a $2 billion share repurchase.

Becton, Dickinson and Company reported a 10.4% revenue increase in Q3 2025, alongside a strategic plan to combine its Biosciences and Diagnostic Solutions business with Waters Corporation.

Becton Dickinson's Q2 2025 revenues increased by 4.5% year-over-year, driven by the Advanced Patient Monitoring acquisition and growth in key segments, while the company progresses with plans to separate its Biosciences and Diagnostic Solutions business.

Becton Dickinson (BD) reports a 9.8% increase in Q1 2025 revenue and announces plans to separate its Biosciences and Diagnostic Solutions business.

Becton Dickinson's Q3 2024 results show a revenue increase of 2.3% year-over-year, alongside the announcement of a $4.2 billion acquisition of Edwards Lifesciences' Critical Care product group.

Becton, Dickinson and Company announced an 8.2% increase in worldwide revenues for fiscal year 2025, driven by strategic acquisitions and strong segment performance, while also detailing significant portfolio adjustments.

Becton Dickinson's 2024 annual report highlights a year of strategic acquisitions and growth, alongside challenges from regulatory actions and global economic pressures.

Michael Feld, EVP, Chief Revenue Officer of Becton Dickinson & Co, sold 75 shares of common stock on July 27, 2026 for $157.13 per share.

Bilal Muhsin, EVP & President Connected Care at Becton Dickinson, reported a net acquisition of 12,407 shares following the vesting and tax withholding of restricted stock units.

Michael Feld, EVP and Chief Revenue Officer at Becton Dickinson & Co., has sold 75 shares of common stock valued at $152.80 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Michael David Garrison, EVP & Pres Med.Essntl&BioPharm at Becton Dickinson & Co, sold 1,100 shares of common stock on June 24, 2026, for $145.66 per share.

Becton Dickinson EVP Michael Garrison sold 1,100 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Thomas E. Polen Jr., Chairman, CEO, and President of Becton Dickinson & Co., reported significant stock transactions on June 1, 2026, including sales and acquisitions under a Rule 10b5-1 plan.

Becton, Dickinson and Company has filed definitive additional proxy materials with the SEC.

Becton, Dickinson and Company announces its new 'Excellence Unleashed' growth strategy, following record fiscal year 2025 revenues of $21.8 billion and a strategic portfolio simplification.

Becton, Dickinson and Company files a definitive proxy statement with the SEC.

Becton Dickinson (BD) delivered strong financial results in fiscal year 2024, driven by its BD 2025 strategy and key acquisitions.

Vanguard Capital Management has reported a beneficial ownership of 7.51% in Becton Dickinson & Co. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 15,388,359 shares, representing 5.4% of the outstanding common stock of Becton Dickinson & Co.

The Vanguard Group has filed an amended Schedule 13G for Becton Dickinson & Co, reporting 0% beneficial ownership following an internal realignment.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 12.85% beneficial ownership in Becton Dickinson & Co.

T. Rowe Price Investment Management, Inc. has reported a 5.6% beneficial ownership stake in Becton Dickinson and Co. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a passive beneficial ownership of 11.27% in Becton Dickinson & Co's common stock as of June 30, 2025.